Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metoclopramide hydrochloride monohydrate, quantity: 10 mg - tablet, film coated - excipient ingredients: maize starch; macrogol 6000; colloidal anhydrous silica; microcrystalline cellulose; purified talc; stearic acid; pregelatinised maize starch; hypromellose; titanium dioxide - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharma ltd - metoclopramide hydrochloride - solution for injection - 5mg/1ml

United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 5 mg in 1 ml - diabetic gastroparesis (diabetic gastric stasis) metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy metoclopramide injection, usp is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy. the prevention of postoperative nausea and vomiting metoclopramide injection, usp is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable. small bowel intubation metoclopramide injection, usp may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. radiological examination metoclopramide injection, usp may be used to stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and/or small intestine. metoclopramide should not be used whenever stimulation of gastrointestinal motility might be dangerous, e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction or perforation. metoclopramide is contraindicated in patients with pheochromocytoma because the drug may cause a hypertensive crisis, probably due to release of catecholamines from the tumor. such hypertensive crises may be controlled by phentolamine. metoclopramide is contraindicated in patients with known sensitivity or intolerance to the drug. metoclopramide should not be used in epileptics or patients receiving other drugs which are likely to cause extrapyramidal reactions, since the frequency and severity of seizures or extrapyramidal reactions may be increased.

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - metoclopramide hydrochloride, anhydrous - solution for injection - metoclopramide hydrochloride anhydrous 5 mg/ml - drugs for functional gastrointestinal disorders

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - metoclopramide hydrochloride, anhydrous - injection - metoclopramide hydrochloride anhydrous 5 mg/ml - drugs for functional gastrointestinal disorders

Malta - English - Medicines Authority

health house pharma ltd t/as p&d pharmaceuticals ltd 38 woolmer way, bordon, hampshire, gu35 9q, united kingdom - metoclopramide hydrochloride, anhydrous - injection - metoclopramide hydrochloride anhydrous 5 mg/ml - drugs for functional gastrointestinal disorders

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - metoclopramide hydrochloride - solution for injection - metoclopramide hydrochloride 5 mg/ml - drugs for functional gastrointestinal disorders

Israel - English - Ministry of Health

raz pharmaceutics ltd, israel - metoclopramide hydrochloride - solution for injection - metoclopramide hydrochloride 5 mg/ml - metoclopramide - metoclopramide s.a.l.f 10 mg/2 ml is indicated in adults for: - prevention of postoperative nausea and vomiting (ponv) - prevention of delayed nausea and vomiting caused by chemotherapy (delayed cinv) - prevention of nausea and vomiting caused by radiation therapy - symptomatic treatment of nausea and vomiting, including nausea and vomiting caused by migraine attack. in migraine attacks, metoclopramide can be used concomitantly with oral analgesics to improve their absorption. - diabetic gastroparesis - to faciliate diagnostic procedures (ie, to faciliate small bowel intubation and as an aid in radiological examinations) pediatric population. metoclopramide s.a.l.f 10 mg/2 ml is indicated in children aged 1 to 18 years for: - second line-therapy: treatment of established postoperative nausea and vomiting (ponv) - second-line therapy: prevention of delayed nausea and vomiting caused by chemotherapy (delayed cinv) - to facilitate diagnostic procedures (ie, to faciliate small bowel intubation and as an aid in radiological examinations).

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - methadone hydrochloride 5 mg/ml - oral solution - 5 mg/ml - active: methadone hydrochloride 5 mg/ml excipient: caramel cherry flavour it1037 citric acid monohydrate glycerol hyetellose purified water sodium benzoate xylitol - indicated in detoxification and maintenance treatment as a substitute for heroin or other morphine-like drugs to suppress the opiate-agonist abstinence syndrome in patients who are dependent on these drugs.

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg - the use of metoclopramide  tablets, usp is recommended for adults only. therapy should not exceed 12 weeks in duration. symptomatic gastroesophageal reflux:  metoclopramide tablets, usp are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. diabetic g